Constraint-induced movement therapy and massed practice. by van der Lee, J.H. et al.
VU Research Portal
Constraint-induced movement therapy and massed practice.





Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
van der Lee, J. H., Lankhorst, G. J., Bouter, L. M., & Wagenaar, R. C. (2000). Constraint-induced movement
therapy and massed practice. Stroke, 31, 988-9.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 21. May. 2021
Seemant Chaturvedi
Attacks • Response to Dr Chaturvedi:
Supplement to the AHA Guidelines for the Management of Transient Ischemic
ISSN: 1524-4628 
Copyright © 2000 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
2000, 31:983-991Stroke 
http://stroke.ahajournals.org/content/31/4/983.1
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
http://www.lww.com/reprints




Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
http://stroke.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Stroke is online at 
 at Vrije on July 29, 2011http://stroke.ahajournals.org/Downloaded from 
Strokewelcomes Letters to the Editor and will publish them, if suitable, as space permits. They should not exceed 1000 words (excluding references)
and may be subject to editing or abridgment. Please submit letters in duplicate, typed double-spaced. Include a fax number for the corresponding author and
a completed copyright transfer agreement form (published in the January and July issues).
Supplement to the AHA Guidelines for the
Management of Transient Ischemic Attacks
To the Editor:
I read with interest the recent supplement to the guidelines on
management of patients with transient ischemic attacks.1 How-
ever, with regard to carotid endarterectomy (CE), I was disap-
pointed that Albers et al made no attempt to interpret the clinical
trial results in the context of real-world surgical performance.
For example, in the updated section on CE for 50% to 69%
symptomatic stenosis, the authors state that symptomatic patients
with 50% to 69% benefit from surgery and that these patients
should be considered for CE. However, should clinicians con-
clude that because patients in the surgical arm of the North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) had a marginal statistically significant benefit
(P50.045) that this result is clinically meaningful and that this
can be routinely achieved in clinical practice?
One must keep in mind that the benefit of surgery in the 50%
to 69% group was very modest. For the important clinical
outcome of disabling, ipsilateral stroke, the absolute difference
between the medical and surgical groups was only 4.4% at 5
years, or less than 1% per year.2 This modest result was achieved
in the ideal setting of low-risk patients being operated on by
surgeons screened for their excellence. In NASCET as a whole,
the perioperative mortality was 1.1% and the stroke and death
rate was 6.5%.
In terms of the real world, Wennberg et al3 analyzed CE
results in over 100 000 Medicare beneficiaries in 1992–1993 and
found the perioperative mortality at an average volume hospital
to be 1.9%. This was in a mixed symptomatic/asymptomatic
cohort. Had the analysis been restricted to symptomatic patients
only, the perioperative mortality would likely have been even
higher.
With regard to other recent studies, Hartmann et al4 studied
symptomatic patients over a two year period at their hospital and
the stroke/death rate was 11.1%. In the Carotid and Vertebral
Artery Transluminal Angioplasty Study (CAVATAS), the rate of
disablingstroke and death in the CE group was 5.9%, almost 3
times as high as the NASCET figure (M. Brown, personal
communication, 1999).
With these considerations, I think that the extremely modest
benefit seen in the high-moderate NASCET group is not gener-
alizable and that these patients will not benefit from CE in the
real world. The comments of Wennberg et al3 on the utilization
of CE should be heeded when these authors stated that “the
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To the Editor:
I must respectfully disagree with the recent AHA Scientific
Statement on the management of transient ischemic attacks.1
First, the inclusion of the combination antiplatelet agent
extended release dipyridamole and aspirin (ERDP/ASA) as a
“recommended therapy” is premature. The current data are
insufficient to definitively establish that ERDP/ASA offers
anything in addition to aspirin alone. Although the results of the
ESPS-2 trial2 of ERDP/ASA are encouraging and generate great
optimism for this and other combination strategies, serious
questions remain. The ESPS-2 results are highly inconsistent
with previous data on 5317 patients treated with the combina-
tion.3 Although a heterogeneous set of trials, these data were
sufficient to all but abandon use of dipyridamole in the 1980s.
Further, the high rate of subject dropout,2 the lack of any benefit
in vascular death despite the stunning benefit in stroke,2 the
50-mg dose of ASA,2,4 and the scientific misconduct5 discovered
in the trial collectively make ESPS-2 inadequate to certify
ERDP/ASA as an established therapy by the AHA or any other
body.6 Any new scientific finding that is a large departure from
previous data or theory requires independent conformation. Such
is true of ERDP/ASA.
Second, a variety of commonly used antithrombotic strategies
deserve mention with ERDP/ASA as potentially useful, if un-
proven, alternatives. This includes the use of clopidogrel or
ticlopidine with aspirin,7–9 a well-accepted standard for post-
stenting prophylaxis. For some warfarin patients, the addition of
any antiplatelet agent can help also.10,11 Further, for those who
are impressed with the dramatic ESPS-2 results of ERDP/ASA,
comparable efficacy was observed in the ESPS-1 trial using the
inexpensive (and currently available) combination of aspirin
(325 mg) and regular dipyridamole (75 mg) 3 times a day.12
Time and more data will tell if any of these combinations,
ERDP/ASA included, can be recommended for general use.
Richard L. Hughes, MD
University of Colorado School of Medicine
Denver, Colorado
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Response to Dr Chaturvedi:
We thank Dr Chaturvedi for his comments regarding the
carotid endarterectomy recommendations in the recently pub-
lished American Heart Association Guidelines for the Manage-
ment of Transient Ischemic Attacks. We agree that the efficacy
of therapies in the community setting, medical or surgical, may
differ from the results obtained in carefully controlled clinically
trials. Application of clinical trial results to clinical practice is
always problematic and requires clinical judgement. We also
agree that surgical morbidity and mortality rates may be higher in
the “real world” than those achieved in the North American
Symptomatic Carotid Endarterectomy Trial (NASCET). How-
ever, the stroke and death rate is also likely to be higher in
medically managed patients in a routine practice setting due to
variations in the management of comorbid risk factors, decreased
emphasis on medical compliance, and less frequent systematic
follow-up. In addition, patients selected for participation in
clinical trials frequently have relatively favorable outcomes in
both active treatment and control groups. Therefore, we do not
think it is valid to compare the surgical morbidity and mortality
rates in populations such as Medicare beneficiaries with the rates
observed in a clinical trial. It is also noteworthy that the
NASCET trial enrolled patients with moderate carotid stenosis at
106 diverse clinical sites; therefore, the complication rates
reported do exist in the “real world.”
Our evidence-based guidelines rely heavily on scientific data
from randomized clinical trials. The NASCET and European
Carotid Surgery Trial (ECST) provide the highest quality data
regarding the risks and benefits of carotid endarterectomy for
patients with moderate symptomatic stenosis. The guidelines
state that carotid endarterectomy should be “considered” for
patients with a recent transient ischemic attack or minor stroke
with ipsilateral carotid stenosis of 50% to 69%, but that “the
absolute benefit of surgery is relatively small for these patients.”
The degree of benefit “is highly dependent on surgical risk” and
“consideration should be given to clinical features that influence
stroke risk and surgical morbidity.” These features should
include the overall health and gender of the patient, the nature of
the neurological symptoms, the degree of stenosis, and the
availability of a surgical team with a demonstrated low periop-
erative morbidity and mortality rate.
Response to Dr Hughes:
We appreciate the opportunity to respond to Dr Hughes. After
carefully considering his concerns, we do not believe any
modifications of the American Heart Association recommenda-
tions1 are justified. A balanced review of all available data
regarding the efficacy of the combination of aspirin/dipyridam-
ole was recently published.2 When all studies performed in
cerebrovascular patients are considered, a substantial and statis-
tically significant benefit of aspirin/dipyridamole over aspirin
therapy alone for stroke prevention was detected. The most
compelling data supporting the benefits of this combination
come from the second European Stroke Prevention Study
(ESPS-2) trial that evaluated an extended-release form of dipyr-
idamole (400 mg/d) in combination with aspirin (50 mg/d).3 As
discussed in detail in our report,1 there is no evidence that the
50-mg dose of aspirin is any less effective for stroke prevention
than higher doses, and the aspirin dose recommended by the
Food and Drug Administration for stroke prevention is 50 to 325
mg/d. The “scientific misconduct” referred to by Dr Hughes in
the ESPS-2 trial reflects a single fraudulent investigator who was
identified prior to study completion. The data supplied by this
investigator were removed prior to unblinding and analyzing the
ESPS-2 data and did not influence the results of study. The
dropout rate in the ESPS-2 study did not differ from many
similar stroke prevention trials. In addition, a high dropout rate
typically dilutes, rather than accentuates, the benefits of an
effective agent. The failure of ESPS-2 to demonstrate a reduction
in vascular death is also not unique to the aspirin/extended-
release dipyridamole combination; neither ticlopidine, clopi-
dogrel, nor any single trial of aspirin therapy has demonstrated a
significant reduction in vascular death in patients with cerebro-
vascular disease.
The American Heart Association is not the first group to
recognize the aspirin/extended-release dipyridamole combina-
tion as a safe and effective therapy for stroke prevention—this
combination was recently approved by the Food and Drug
Administration. Other combinations of antiplatelet agents or
anticoagulants have not been adequately tested in stroke or
transient ischemic attack patients. Therefore, their safety and
efficacy are not established.
Gregory W. Albers, MD
Stanford Stroke Center
Stanford University School of Medicine
Palo Alto, California
Robert G. Hart, MD
Department of Medicine/Neurology
The University of Texas Health Science Center at San Antonio
Helmi L. Lutsep, MD
Oregon Stroke Center
Oregon Health Sciences University
Portland, Oregon
David W. Newell, MD
Department of Neurological Surgery
University of Washington School of Medicine
Seattle, Washington
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Which Targets Are Relevant for Therapy of
Acute Ischemic Stroke?
To the Editor:
The report by Heiss et al1 describing ranges of cerebral blood
flow (CBF) decline in 10 patients studied within 3 hours of
984 Letters to the Editor
 at Vrije on July 29, 2011http://stroke.ahajournals.org/Downloaded from 
stroke onset using the PET technique of intravenous [15O]H2O
injection was intended by the authors to spark discussion.
Characterizing the ischemic region into segments that are se-
verely hypoperfused, the ischemic core, moderately hypoper-
fused, the ischemic penumbra, and minimally hypoperfused or
normal will likely provide important information to guide ther-
apeutic options and to determine if any acute treatment at all
should be used.2,3 The data presented by Heiss et al imply that
most of the ischemic territory in the patients studied were
critically hypoperfused, ie, with CBF levels below 12 mL/100 g
per minute, while the penumbral and “sufficiently perfused”
components were small, accounting for on average only 18% and
12% of the finally infarcted volume, respectively. The authors
suggest that such critically hypoperfused ischemic tissue be-
comes irreversibly injured rapidly and that “only fast and
effective reperfusion strategies” can be potentially useful. The
implications suggested by the authors are far reaching, as they
imply that only very early (1 to 2 hours) thrombolysis will save
the bulk of the at-risk tissue, while the remainder, made up of the
penumbra and the sufficiently perfused tissue, may be salvage-
able by neuroprotective and agents directed against delayed
neuronal death (such as anti-inflammatory and antiapoptosis
agents), respectively. However, according to the authors, the fact
that only small amounts of these latter two tissue subtypes are to
be found explains the failure or only marginal efficacy of clinical
trials of such pharmacological agents, so that it will be necessary
to combine them with early thrombolysis to demonstrate their
beneficial effects. These conclusions are provocative and intrigu-
ing but differ from prior PET studies using more conventional
techniques to measure CBF (and also assessing CMRO2 and the
OEF), which have not demonstrated that the critically hypoper-
fused region is as extensive as the data provided by [15O]H2O
technique, although these prior PET studies were not as hyper-
acute as the current study.4–6 This observation is also discrepant
with several recent diffusion-perfusion MRI studies that show
approximately 70% of stroke patients studied within 6 hours of
onset have substantially greater perfusion than diffusion ische-
mic lesion volumes.7,8 Diffusion abnormalities likely represent
ischemic regions with very low CBF levels. If the patients
studied by Heiss et al underwent concurrent diffusion-perfusion
MRI, it would be expected that most of the patients would have
had diffusion lesions approximating the perfusion lesions. An
interesting area for a future study would, therefore, be to perform
PET and diffusion-perfusion MRI studies in a group of acute
ischemic stroke patients in whom the two studies could be
obtained with a close temporal relationship.
The identification of the degree of hypoperfusion with the
[15O]H2O is critically dependent on the accuracy of the method
and its interpretation. Does the [15O]H2O method accurately
characterize CBF decline? In theory, the answer is yes. However,
because of the use of rtPA, the authors could not apply a fully
quantitative method, which implies arterial catheterization. So
instead they used a semiquantitative version of the method, in
which the CBF is estimated from the side-to-side asymmetry in
15O count-rates on the scans. However, the one paper cited to
support this approach is in a nonreferenced source, and further
documentation is critical.
In their article, Heiss et al propose what is effectively a novel
3-compartment model of ischemic tissue that comprises (1) a
critically hypoperfused component (with CBF,12 mL/100 g per
minute), which inevitably undergoes necrosis if not rapidly
reperfused; (2) a penumbral component (with CBF in the 12 to
18 mL/100 g per minute range), which may spontaneously
survive and could be salvageable by neuroprotective agents (and
perhaps also by thrombolysis); and (3) a sufficiently perfused
component (with CBF.18 mL/100 g per minute), which may,
however, suffer delayed neuronal death and thus be incorporated
in the final infarct. This is an interesting model that the authors
propose to explain the results of therapeutic trials in humans, but
they do not offer evidence to support its validity. Based on the
classic monkey studies of Symon, Astrup and coworkers, and
Jones and colleagues of the dynamic penumbra model, most
authors consider also 3 compartments but their operational
definitions are different, with (1) the core of severely hypoper-
fused (and hypometabolic) tissue representing the irreversibly
damaged tissue at any particular point in time; (2) the penumbra
representing all the tissue that can be saved from infarction
(taken here to represent pannecrosis, but disregarding selective
neuronal death, which is a very marginal occurrence in focal
human stroke); and (3) the mildly hypoperfused (“oligemic”)
tissue, which is not normally at risk of infarction unless some
secondary event occurs (such as a fall in systemic blood pressure
or severe brain swelling).9–12In a paper published in 1998, Heiss
et al documented that early thrombolysis (,3 hours) was able to
entirely salvage the critically hypoperfused compartment (,12
mL) in many patients, which would perfectly fit with the classic
findings in the monkey that led to the concept of the penumbra.13
Quantitative PET studies also support this classic model and
have allowed determination of validated, probabilistic CBF
thresholds during the initial 5- to 18-hours interval after stroke,
with CBF ,'8, '8–17, and.17 mL/100 g per minute, for the
core, the penumbra and the oligemic tissue, respectively, accord-
ing to a voxel-based mapping approach in which both gray and
white matters are considered.14,15 Heiss et al use for the core a
CBF threshold value of 12 mL, but this value is from early,
low-resolution PET studies in which patients were rarely scanned
before 24 hours after stroke; moreover, it was calculated from
large gray matter ROIs, so that to apply it at the voxel level is
questionable, or at least would need to be validated.16,17 If a
threshold for irreversible damage is assumed, it would most
likely be much lower than 12 mL, probably around 5 mL or so
in the first 3 hours of stroke, which means that the “core” of
Heiss et al likely includes both already irreversibly damaged and
still-salvageable “at-risk” tissue. Conversely, both their “penum-
bra” and “sufficiently perfused” tissue are at risk of frank
infarction and thus would be incorporated within the penumbra
with the classic model. Although it is difficult to strictly compare
the findings of Heiss et al with those of Marchal et al, as the
individual patient data are not presented in the former, the
discrepancies seem more apparent than real, if one takes into
account these differences in the models.6 Thus, in the Heiss
article, the extreme percentages of final infarct volumes for the
combined penumbra and sufficiently perfused compartments are
8.4% and 63%, consistent with the data of Marchal et al, who
reported that the penumbra occupied 10% to 52% of the final
infarct (mean 32%) with PET scanning done 5 to 16 hours after
onset.
The authors suggest only rapid and effective restoration of
blood flow could salvage the large amount of critically hypoper-
fused ischemic tissue identified by the [15O]H2O CBF method.
Although it remains unknown how long such critically hypoper-
fused tissue will require to evolve, it is likely not to be very long
to permit successful lysis. Since most patients who receive
intravenous tPA in the community do so between 2 and 3 hours
after stroke onset and yet still derive some benefit, it is unlikely
that reperfusion induced by tPA is salvaging only critically
hypoperfused tissue to provide clinical improvement. Addition-
ally, in the recently completed PROACT-II study,18,19 intraarte-
rial thrombolysis initiated with a median time to treat of 5.2
hours demonstrated clinical improvement associated with suc-
cessful reperfusion 2 hours after therapy was begun in 67% of
treated patients. In these patients with angiographically docu-
mented, proximal middle cerebral artery occlusions, it is difficult
to conjecture that large volumes of critically hypoperfused
ischemic tissue could remain potentially salvageable for such an
extended time period. We presume that the likely target for both
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thrombolytic and neuroprotective therapies for acute ischemic
stroke is not likely to be critically hypoperfused ischemic tissue,
but instead moderately hypoperfused regions, ie, the ischemic
penumbra. It is therefore necessary to have accurate, reliable, and
validated imaging methods available to assess blood flow distur-
bances and the tissue consequences induced by these distur-
bances to characterize how the ischemic tissue evolves and
responds to therapeutic interventions. However, this goal will
require the use of both validated methods for CBF assessment
and validated pathophysiological models of brain ischemic
derangements.
Marc Fisher, MD
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Response
It is generally accepted that ischemic stroke in evolution is a
highly dynamic process involving numerous independent factors
and dependent variables. However, in particular the concept of
the ischemic penumbra is rather controversial, as can be seen
from the various notions provided in the letter of Drs Baron and
Fisher. The study described in our contribution was not intended
to consolidate those discrepant views. Therefore, out of the many
blood flow compartments in the ischemic hemisphere, we fo-
cused only on those 3 constituting the ultimate infarct, while
regions not undergoing infarction were intentionally left unana-
lyzed because their fate may have been largely determined by
various therapeutic efforts. Therefore, arguments pertaining to
the total penumbral zone, including both salvaged and eventually
infarcted tissue, are futile, since we had no intention of contra-
dicting observations of widespread severe ischemia that does not
necessarily turn into infarction (as indicated, for example, by
larger lesions in perfusion compared with diffusion-weighted
MRI scans1,2 and by eventually salvaged, mixed gray/white
matter regions exhibiting very low blood flow, even at the
postacute stage).3
We appreciate the enthusiasm of Drs Baron and Fisher in
taking up the discussion we wanted to spark. However, in our
view, time would appear to have come to argue about real data
rather than concepts. Therefore, what is needed is confirmation
or rejection of our findings in appropriate neuroimaging studies
performed very early in the evolution of ischemic stroke, ie., at
a time when blood flow reveals more of its factorial and not so
much of its dependent nature that readily prevails at later points
in time, as exemplified by the studies of Furlan et al,4 in which
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Constraint-Induced Movement Therapy and
Massed Practice
To the Editor:
Van der Lee and coworkers1 reported that Constraint-Induced
Movement (CI) therapy, compared with bimanual neurodevelop-
mental treatment (NDT), results in clinically insignificant im-
provements in the function of the more-impaired arm of persons
with chronic stroke. This small effect stands in contrast to the
very large improvements in real-world arm use obtained with CI
therapy in 3 published studies2–4 (effect sizes 1.9 to 2.8, Motor
Activity Log (MAL); 2,5 large effect size 0.8),6 an as-yet-
986 Letters to the Editor
 at Vrije on July 29, 2011http://stroke.ahajournals.org/Downloaded from 
unpublished placebo-controlled study from our laboratory (effect
size 2.5, MAL),7,8 2 conference presentations,9,10 and pilot
studies from 6 laboratories involved in a national clinical trial of
CI therapy with patients with subacute stroke (E. Taub, S. Wolf,
C. Winstein, C. Giuliani, D. Good, K. Light, C. Kulkulka, D.
Nichols, unpublished data, 1998). Van der Lee et al did not
obtain a large treatment effect with their experimental group
because the intensity of the therapy provided was inadequate and
the subjects selected did not have a large enough deficit before
treatment to show substantial benefits from therapy. In addition,
we argue that the CI therapy group did not show significantly
greater improvement than the bimanual NDT group because this
group does not present an appropriate comparison.
In this laboratory, primary attention in CI therapy administra-
tion is given to training patients on a massed practice basis.2,7,8
Patients perform repetitive, behaviorally relevant arm move-
ments with short intertrial and intertask rest periods for 6 to 7
hours daily for at least 2 consecutive weeks. Supervision is
provided by a therapist on a continuous, one-on-one basis to
ensure intensive practice.11,12 Van der Lee et al1 indicate that
their experimental patients were treated in groups of 4 by 1 or 2
therapists and that tasks included housekeeping activities, hand-
icrafts, and games. It is unlikely that this treatment format
provided patients with adequately intensive practice. When van
der Lee and a coauthor visited our laboratory for a week, they
described their intended procedure in detail as the performance
of hobby-type activities and some ADLs in a relaxed atmosphere
without any systematic attempt to get patients to use the
more-affected extremity intensively. The actual conduct of the
therapy in this fashion was confirmed in a later letter from van
der Lee. Before the investigators left this facility, they were
strongly advised by 2 senior staff members (J. Crago, MSPT, and
S. DeLuca, MA) that what they were planning to do would not
work well because it was not sufficiently intense. Their protocol
appeared so diffuse that they were told that it would test the
minimum intensityof practice needed to produce a clinically
meaningful effect.
The upper cutoff for experiment intake in our laboratory is a
score of 2.5 (less than half as much use of the more-impaired
extremity as before the stroke) on the Amount of Use (AOU)
scale (range 0 to 5) of the Motor Activity Log (MAL), a
semistructured interview of extremity use in the life situation.2,5
This cutoff is used because the brain injuries of stroke patients
impose an upper physiological limit on the amount of improve-
ment that can be produced (a score of 4 on the AOU scale
represents “almost normal use”). Furthermore, patients with
scores.2.5 do not suffer importantly from “learned nonuse,”
which is defined as diminished extremity use in the real-world
setting relative to ability as measured by a laboratory motor test.
Learned nonuse is the target of CI therapy. The mean pretreat-
ment score of experimental subjects in the study of van der Lee
et al1 is 2.2 (SD51.0), which is significantly greater than the
scores (mean51.1, SD50.7, n540) of patients in our experi-
ments (P,0.001). The high score indicates that (1) a large
minority of patients in the experimental group were too high
functioning to have been included in any of the studies cited in
the first paragraph and (2) there was little room for treatment-
induced improvement in extremity use in the experimental group.
In addition, the experimental subjects were higher functioning
than their reference subjects on most measures, particularly the
MAL, before treatment, thus decreasing the opportunity for
improvement relative to the reference group.
In using a reference group given bimanual training based on
NDT for 6 hours per day, van der Lee et al ignore our reports that
conventional physical therapy, when administered in massed
practice fashion, produces an effect that is as good as treatment
involving training of the more-affected extremity and restraint of
the less-affected extremity.5,7,8,13 These data, in combination
with other findings,5,7,8,13have identified the effective therapeu-
tic factor in CI therapy as being the massing or concentration of
practice,howeverachieved. It is primarily this factor that is
thought to give rise to the massive increase in use-dependent
cortical reorganization14 and other large changes in brain activ-
ity9,15,16that appear to be the basis of the long-term changes in
motor function reported by us.2–4,8,12 In this light, the (small)
treatment effect for the bimanual NDT reference group is to be
expected. There are no articles evaluating NDT on nearly as
concentrated a basis as employed by van der Lee et al; in effect,
they had 2 experimental groups receiving what could be consid-
ered 2 different forms of attenuated CI therapy.
Van der Lee et al1 also criticize the MAL on the grounds that
it is a subjective measure and has no established validity.
Although the MAL relies on self-report, it is a psychometrically
robust instrument. The MAL is stable over a 2-week waiting
period3 and over a 2-week placebo treatment period,7,8,13 and it
has (1) high internal consistency (Cronbach’sa50.88 to 0.95),
(2) high interrater reliability (patient compared with primary
caregiver, intraclass correlation type [3,1]17 50.90),5 and (3)
high test-retest reliability (r50.94,P,0.01). Evidence of valid-
ity includes the 0.90 correlation between patient and caregiver
reports, a perfect correlation with an observational measure of
arm use (Actual Amount of Use Test),5,7 and a strong association
between gains on the MAL and brain reorganization.9,14–16
The research from this laboratory was supported by grants
B93–629AP and B95–975R from the Rehabilitation Research
and Development Service, US Department of Veterans Affairs,
and grant HD 34273 from the National Institutes of Health.
Edward Taub, PhD
Gitendra Uswatte, MA
Birmingham Veterans Affairs Medical Center
and Department of Psychology
University of Alabama at Birmingham
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Response
We agree with Drs Taub and Uswatte that the results of the
single-blind, randomized, controlled trial we published1 seem to
contradict the results of the studies published by Taub et al,2
Miltner et al,3 and Kunkel et al.4 There are, however, important
methodological differences between the studies mentioned by
Taub and Uswatte and our study, and we consider this to be the
most probable explanation of the apparent differences in results.
Obviously, we are unable to comment on the unpublished studies
mentioned by Taub and Uswatte. The studies presented by
Kunkel et al and Miltner et al are uncontrolled case-series
studies. Uncontrolled studies can be misleading and will almost
always report grossly overestimated treatment effects.5 There are
2 principal methodological differences between the randomized
trial published by Taub et al2 and our study: the number of
patients (9 versus 66, respectively) and the intervention in the
control group (“attention-control” versus intensive bimanual
treatment, respectively). The contrast between the so-called
“attention-control” intervention and the experimental interven-
tion applied by Taub et al comprises not only specific but
obviously also nonspecific aspects. In our opinion, this is
illustrated by Figure 3 included in the article of Taub et al, in
which half of the effect of the treatment in the experimental
group appears to take place on day 1 of the treatment. In their
letter, Taub and Uswatte mention 3 tentative explanations as to
why we did not find a greater treatment effect: inadequate
intensity of therapy, inadequate selection of patients, and inad-
equate contrast between the experimental and the control inter-
ventions. Furthermore, they contradict our criticism of the Motor
Activity Log (MAL). We will reply to each of these
items separately.
Intensity of treatment.We are somewhat puzzled by this criticism
from Taub and Uswatte, because it is contradicted by their later
statement that the improvement in our reference group was the result
of the high intensity of treatment (“concentrated schedule of
delivery”). Indeed, the intensity of treatment was high in both the
experimental and the reference groups in our trial.
Selection of patients.It is true that we used a different outcome
measure to the MAL to establish the upper cutoff for inclusion in
our study, ie, the Action Research Arm (ARA) test, which was a
primary outcome measure in our study. It is, indeed, conceivable
that at higher pretreatment levels the MAL suffers from a ceiling
effect. Nevertheless, we did find differential effects on the MAL,
but these did not last.1 To investigate the assumption that a more
rigourous selection of patients would have yielded greater
treatment effects, we reanalysed the subgroup of patients in our
trial whose pretreatment MAL Amount Of Use (AOU) score was
,2.5, as suggested by Taub and Uswatte. Somewhat to our
surprise, however, we did not find a statistically significant
difference in effectiveness in this subgroup (n543), the mean
difference in improvement on the MAL AOU scale between
groups being 0.32 points (95% CI20.10 to 0.75). This means
that it could also be argued that higher-scoring patients are more
liable to improve than patients with less residual arm function.
On the ARA test, the difference in improvement between groups
was significant in this subgroup, ie, 3.4 points (95% CI 1.3 to
5.6) and not notably different from the effect in the entire study
population, ie, 3.0 points (95% CI 1.3 to 4.8).
Contrast between the experimental and the control inter-
ventions.We agree that the contrast between the experimental
and the control interventions in our trial was relatively small.
The main objective of our study was to investigate thesp cific
effect of forced use, ie, the immobilization of the unaffected
arm. We tried to make the control treatment equally intensive,
to adjust for the nonspecific effects of treatment intensity. It
is, indeed, conceivable that the intensity of the treatment is the
most effective aspect of the treatment, designated as
constraint-induced movement therapy, but this has not yet
been shown in publications of well-designed studies in peer-
reviewed journals. As we stated in the discussion paragraph of
our article, the improvement in the control group may very
well have been the result of the intensive physical and
occupational therapy, which was equally intensive in the
experimental group. The use of a splint and sling to immobi-
lize the unaffected arm is very unpleasant and potentially
dangerous. If a similar effect can be obtained by intensive
bimanual treatment, this is of crucial importance for clinical
practice. This would imply that the term “constraint-induced”
can be replaced by “intensive.” The effectiveness of enhanced
intensity of treatment for stroke patients has recently been
shown by Kwakkel et al.6
Validity and reliability of the MAL.The statement that the
MAL is stable over a 2-week waiting period is not confirmed by
the data presented by Miltner et al.3 The MAL AOU and Quality
Of Movement (QOM) data differ significantly between first
contact and baseline (AOU,P50.023; QOM,P50.047), and
between baseline and pretreatment (AOU,P50.006; QOM,
P50.022), respectively (Wilcoxon signed rank test). In 2 of the
articles claimed to confirm the stability of the MAL over a
6-week placebo treatment and follow-up period, no data were
presented.7,8 More importantly, the possibility that reported
changes on the MAL are the result of a Hawthorne effect remains
unchallenged.
We hope that the readers, when weighing up the arguments in
the letter from Taub and Uswatte and our reply to their criticism,
will not forget that to date only 2 randomized controlled trials1,2
on the question at issue have been published, of which ours1 is by
far the largest. We therefore wish to reemphasize the importance
of our findings. We hope that the positive aspect of our
conclusion, that the effect of forced use was clinically relevant in
subgroups of patients with sensory disorders and hemineglect,
will be a challenging starting point for future research.
Johanna H. van der Lee, MD
Gustaaf J. Lankhorst, MD, PhD
Department of Rehabilitation Medicine
University Hospital Vrije Universiteit
Institute for Research in Extramural Medicine
Lex M. Bouter, PhD
Institute for Research in Extramural Medicine
Vrije Universiteit
Amsterdam, The Netherlands
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Effects of Statins on Ischemic Stroke:
Neuroprotection and/or Triggering of
Apoptotic Damage?
To the Editor:
In their recent review, Drs Vaughan and Delanty1 have
proposed that statins, which inhibit the activity of a key enzyme
in the biosynthesis of cholesterol and isoprenoids (b-hydroxy-
methyl-b-glutaryl coenzyme A reductase), may represent a
clinically important class of drugs in human neuroprotection.
This proposal is first based on the results of clinical trials and
meta-analysis indicating that statin therapy lowers stroke risk by
'30%. In addition, several experimental results reviewed by
these authors suggest that statins may act by making the brain
parenchyma cells “more resistant to the effect of ischemia.”
Indeed, statins appear to exert anti-inflammatory and antioxida-
tive properties and to modulate the effects of various cytokines.
Despite the bundle of evidence toward a beneficial action of
statin therapy, it appears to me that some of the effects of statins
that might be less attractive have perhaps been overlooked.
Indeed, there have been in the last few years several reports
showing that inhibition of cholesterol biosynthesis by statins
induces apoptosis in various cellular models, including cortical
neurons in culture,2 human and rat glioma cells,3–5 as well as PC
12 cells.6,7 Similarly, we have shown in PC 12 cells that
mevastatin treatment first induces an aborted differentiation
followed by a programmed cell death (D. Duval, PhD, unpub-
lished data, 1999). Although the mechanisms leading to glioma
and neuronal cell damage are not fully understood, it generally
appears that statins act by inhibiting the isoprenoid pathway and
blocking the isoprenylation of protein(s) involved in the control
of cell proliferation and survival.8–10 It has been shown, for
example, that statin treatment induces a cytoplasmic accumula-
tion of Rho A in renal mesangial cells11 or p21 WAF1 induction
in vascular smooth muscle cells.8
Additional experiments are clearly needed to determine
whether or not such an apoptotic effect of statins may occur in
the brain under either physiological and/or pathological situa-
tions such as trauma and focal ischemia. Michikawa and Yanagi-
sawa2 have described that cultures of cortical neurons become
more susceptible to the toxic action of apolipoprotein E4 under
conditions of de novo suppressed cholesterol biosynthesis. Nev-
ertheless, given the possibility that statins may exert deleterious
effects on brain cells, it is probably prematurate to state that
inhibitors of cholesterol biosynthesis represent potential neuro-
protective agents, and caution should thus be required before
undertaking larger clinical trials in humans.
D. Duval, PhD
Universite de Caen UMR CNRS 6551
Caen, France
1. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral
ischemia and stroke.Stroke.1999;30:1969–1973.
2. Michikawa M, Yanagisawa K. Apolipoprotein E4 induces neuronal death
under conditions of suppressed de novo cholesterol biosynthesis.
J Neurosci Res.1998;54:58–67.
3. Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ. Geranylge-
raniol overcomes the block of cell proliferation by lovastatin in C6 glioma
cells.J Neurochem.1998;70:2397–2405.
4. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for
brain cancer therapy: synergistic activity of lovastatin and sodium phe-
nylacetate against human glioma cells.J Neurochem.1996;55:710–716.
5. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, Law RE.
Lovastatin induces growth inhibition and apoptosis in human malignant
glioma cells.Biochem Biophys Res Commun.1994;205:1681–1687.
6. Sato-Suzuki I, Murota SI. Simvastatin inhibits the division and induces
neurite-like outgrowth in PC 12 cells.Neurosci Lett.1996;220:21–24.
7. Michikawa M, Yanagisawa K. Inhibition of cholesterol production but
not of non sterol isoprenoid products induces neuronal cell death.J Neu-
rochem. 1999;72:2278–2285.
8. Müller C, Kiehl MG, Van de Loo J, Koch OM. Lovastatin induces
p21WAF1/CIP1 in human vascular smooth muscle cells: influence on protein
phosphorylation, cell cycle, induction of apoptosis, and growth inhibition.
Int J Mol Med.1999;3:63–68.
9. Keegan K, Halegoua SS. Signal transduction pathways in neuronal dif-
ferentiation.Curr Opin Neurobiol.1993;3:14–19.
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Response
We thank Dr Duval for his interest in our article1 and
appreciate his concern about potential deleterious effects of
statins within the nervous system, particularly his concern about
the possible induction by statins of apoptosis within the brain.
We agree that any adverse effects of statins should be thoroughly
investigated. Indeed, we drew attention to the possible inhibition
of coenzyme Q10 biosynthesis by lovastatin as one example. We
have a number of additional comments in reply to Dr Duval.
First, our article was essentially hypothesis generating rather than
a statement of fact. The unequivocal demonstration of neuroprotec-
tion with statins in humans must await further study, especially
employing large randomized trials in specific situations, eg, after
acute stroke. In addition, not all statins may exert neuroprotection,
and there may be differential effects within this class.2
Second, our hypothesis was based on published data from studies
of various types, which included large, randomized, placebo-
controlled trials in patients with or at risk of vascular disease;
observational studies using surrogate end points of endothelial
function in humans; relevant animal studies, including important
studies measuring cerebral blood flow in normocholesterolemic
mice; as well as studies using in vitro models. On the other hand, Dr
Duval’s concerns arise from studies exclusively carried out in vitro
utilizing cultured glial cells and neurons. Although of interest, these
studies may be of least relevance when applied to clinical therapeu-
tics and thus need further confirmation in other models. These in
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vitro studies are also apt to be compounded by the specific cell lines
used and drug concentrations. In addition, some of these studies
have used transformed cell lines, such as human malignant glioma
cells and promyelocytic cells, and therefore the data may not be
applicable to healthy but at risk tissue, such as that within the
ischemic penumbra in acute stroke. In one study quoted by Dr
Duval, lovastatin was shown to induce apoptosis in human malig-
nant glioma cells, leading the authors of the study to speculate that
such an approach with statins “merit further investigation as poten-
tial therapeutic agents for the treatment of malignant gliomas.”3
Furthermore, if statins induce apoptosis in both nonmalignant
“healthy” glia as well as in malignant glial cells, it is not intuitively
obvious that this would necessarily be deleterious; in some circum-
stances, the inhibition of active gliosis4 could be beneficial and
ameliorate brain dysfunction. Again, these complex, interesting, and
highly relevant questions can be optimally addressed only in human
studies using clinical outcome data, perhaps in conjunction with
novel noninvasive markers of neuronal function such as magnetic
resonance spectroscopy.
Finally, Dr Duval’s concerns about possible adverse effects of
statins are immediately relevant to the large numbers of patients
worldwide currently taking these drugs. Patients with hypercho-
lesterolemia and those with coronary artery disease are at
significant risk for concomitant disease within the cerebral
vasculature, and it is likely that a large number of patients with
established cerebrovascular disease are already being treated
with various agents of the statin class. We disagree that clinical
trials should be inhibited on the basis of the studies cited by Dr
Duval. There is no evidence in vivo of neurological decline in
patients receiving statin therapy, and the suggestion that these
compounds may be proapoptotic in the normal or ischemic brain
is pure speculation. The points raised by Dr Duval underscore the
need for prospective, randomized, placebo-controlled trials to
explore the efficacy of statin therapy in human neuroprotection.
Ongoing studies such as the The Prospective Study of Pravastatin
in the Elderly at Risk (PROSPER) study5 will help clarify their
role in human cerebrovascular disease.
Carl J. Vaughan, MD
Cardiology Division
Department of Medicine
Weill Medical College of Cornell University
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Frequent Polymorphism of the Human
Methylenetetrahydrofolate Reductase
To the Editor:
In the recent article by Bova et al,1 the authors describe a
significant association of the “alanine/valine (A/V) poly-
morphism at codon 677 of the 5, 10 methylenetetrahydrofolate
reductase (MTHFR) gene.” This polymorphisms was abbre-
viated in the title with A677V. There have been multiple
studies on the impact of this so-called thermolabile variant of
MTHFR and moderate hyperhomocysteinemia and/or athero-
sclerotic vasculopathies. The variant is characterized by a
C3T transition of nucleotide 677.2 Codon 677, which is
described by the authors throughout the paper, is not affected.
Obviously, the authors mixed up the genetic terms nucleotide
position and codon, which may confuse the reader. The
common nomenclature of the MTHFR thermolabile variant is
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Response
We thank Mr Linnebank, Mr Homberger, and Dr Koch for
pointing out the problematic nomenclature of the thermolabile
MTHFR variant. The most accurate description of the mutation
studied in our paper is indeed MTHFR 677C-T.
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We read with interest the article by Bova et al,1 published in
the October 1999 issue ofStroke, on the association of the
MTHFR A677V gene allele with carotid atherosclerosis. We
have just finished a study aimed to characterize very old people
with “vascular successful aging” (VSA), which we define ac-
cording to the following criteria: (1) age$75 years; (2) negative
history for cardiovascular disease; (3) absence of clinical symp-
toms and ultrasonographic/Doppler signs (duplex sonography) of
extracoronary (epiaortic, abdominal aortic, iliac, and femoral)
atherosclerosis, ie, lack of any focal protrusion$1.5 mm; and (4)
absence of clinical symptoms and ECG signs of coronary artery
disease. These subjects were compared with a control group
selected by the following criteria: (1) age$75 years and (2)
presence of carotid atherosclerosis, ie, a plaque inducing a 30%
to 50% stenosis. They may have a positive history for cardio-
vascular disease, provided that no acute episode occurred in the
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3 months before inclusion in the study. A total of 57 subjects, 29
with VSA and 28 with carotid atherosclerosis (AG), were
enrolled. The mean age in both groups was.80 years (80.9 and
81.8, respectively). We found several differences between the
VSA subjects and controls in plasma and LDL antioxidant levels
as well as in LDL oxidation level. Among the possible genetic
markers of vascular successful aging, we also determined the
A677V MTHFR gene polymorphism by the method of Frosst et
al,2 but we did not find any association with the vascular status.
The frequency of the A677V allele was 52% in the VSA group
and 39% in the AG group (x25NS), while the frequency of
homozygosity was 36% in VSA and 10% in the AG group
(x25NS). Genotype frequencies conformed to the Hardy-
Weinberg equilibrium. In the study of Bova et al, the subjects
were significantly younger than in our study and the control
group suffered from mild carotid atherosclerosis. Because ath-
erosclerosis is a progressive disease, subjects with a mild stenosis
in adult age, as the control group presented in the study, might
develop greater stenosis in late life and therefore might not
represent an ideal control for comparison. Moreover, only 19%
of the subjects with severe carotid atherosclerosis were homozy-
gous, a condition that has been clearly associated with increased
homocysteine levels.2
Our results suggest that this polymorphism is not associated with
the presence, or with the absence, of moderate to severe carotid
atherosclerosis in very advanced age. However, it is possible that the
A677V gene polymorphism is associated with atherosclerosis in a
younger population as well as in different ethnic groups.
Because the relationship between A677V gene polymorphism
and carotid atherosclerosis is still controversial,3,4 more research
must be done in this field before any conclusion can be drawn.
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We thank Zuliani and colleagues for describing their
observations on carotid stenosis and the MTHFR 677c-t allele.
As these authors note, their patient population was signifi-
cantly older than the patients in our study and were chosen by
somewhat different criteria. In this population the MTHFR
677c-t allele was less common in patients with moderate
carotid stenosis than in age-matched patients with no signif-
icant cardiovascular disease. Although it is difficult to com-
pare our study with the results of Zuliani et al, the differences
between elderly and younger patients seem to be analogous
with the well-established association of the APOEe4 allele
and Alzheimer’s disease. In the case of APOE, thee4 allele is
associated with earlier age of onset of disease; due to earlier
mortality in Alzheimer’s disease, in the population aged.80
years it is no longer more common in Alzheimer patients than
in controls.1,2
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